Related Experiment Video
Updated: Nov 6, 2025

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
Published on: September 9, 2022
Biomarkers and Surrogate End points in Multiple Sclerosis Trials: Regulatory Issues
1Department of Neurology, Division of Multiple Sclerosis and Neuroimmunology, Duke University Medical Center, Durham, North Carolina, U.S.A.; and.
Summary:
Evoked potentials have assisted in the diagnosis of multiple sclerosis for years, but the potential to demonstrate pathophysiologic change has prompted a reconsideration of their potential role as outcome measures in clinical trials of multiple sclerosis. The use of any surrogate end point or biomarker in clinical trials requires a thorough understanding of that end point's performance characteristics and utility in a particular setting. This article explores regulatory issues regarding the use of biomarkers and surrogate end points in clinical trials of multiple sclerosis with particular emphasis on challenges faced by evoked potential studies.
More Related Videos
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Bioequivalence studies: Biowaivers
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Bioequivalence of Drugs: Drugs with Multiple Indications
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability Study Design: Single Versus Multiple Dose Studies

